BYETTA
offers sustained A1C control with a secondary benefit of weight loss
For
your patients
<<
BYETTA InfoSite Home
Patients
with a baseline A1C of <9% (mean: 7.8%) experienced, on average, a
0.7% reduction in A1C at 2.5 years with BYETTA (n = 182).*[1]
Mean change in A1C from baseline*[1]
was -1.2 % at 30 weeks (n = 241) and -1.1%
at 2.5 years (n = 241)
Mean baseline A1C: 8.3%
BYETTA® offers sustained A1C control with a secondary benefit of weight loss
BYETTA provided a 2.1% reduction in A1C in poorly controlled patients through 2.5 years
Mean baseline A1C: 9.7%
Patients
with a baseline A1C of <9% (mean: 7.8%) experienced, on average, a
0.7% reduction in A1C at 2.5 years with BYETTA (n = 182).*[1]BYETTA sustained reductions in A1C across all patients through 2.5 years
Mean change in A1C from baseline*[1]
was -1.2 % at 30 weeks (n = 241) and -1.1% at 2.5 years (n = 241)
Mean baseline A1C: 8.3%*Initial 30-week double-blind, placebo-controlled
clinical trials were continued in open-label extensions through 130 weeks
with BYETTA
5 mcg or 10 mcg. Subjects (n = 241) received BYETTA 5 mcg BID for
4 weeks, BYETTA 5 mcg or 10 mcg BID for 26 weeks, BYETTA 5 mcg BID for 4 weeks, and BYETTA 10 mcg BID for 96 weeks in combination with metformin, a sulfonylurea, or both. Note: all values are means; data by completer analysis.
5 mcg or 10 mcg. Subjects (n = 241) received BYETTA 5 mcg BID for
4 weeks, BYETTA 5 mcg or 10 mcg BID for 26 weeks, BYETTA 5 mcg BID for 4 weeks, and BYETTA 10 mcg BID for 96 weeks in combination with metformin, a sulfonylurea, or both. Note: all values are means; data by completer analysis.
BYETTA helped most patients lose weight through 2.5 years
*Initial 30-week double-blind, placebo-controlled
clinical trials were continued in open-label extensions through 130 weeks
with BYETTA
5 mcg or 10 mcg. Subjects (n = 241) received BYETTA 5 mcg BID for
4 weeks, BYETTA 5 mcg or 10 mcg BID for 26 weeks, BYETTA 5 mcg BID for 4 weeks, and BYETTA 10 mcg BID for 96 weeks in combination with metformin, a sulfonylurea, or both. Note: all values are means; data by completer analysis.
5 mcg or 10 mcg. Subjects (n = 241) received BYETTA 5 mcg BID for
4 weeks, BYETTA 5 mcg or 10 mcg BID for 26 weeks, BYETTA 5 mcg BID for 4 weeks, and BYETTA 10 mcg BID for 96 weeks in combination with metformin, a sulfonylurea, or both. Note: all values are means; data by completer analysis.
